ANAB
AnaptysBio, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website anaptysbio.com
- Employees(FY) 96
- ISIN US0327241065
Performance
+20.56%
1W
+21.82%
1M
+6.91%
3M
+54.05%
6M
+19.89%
YTD
+21.36%
1Y
Profile
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Investment Analysis Report: ANAB
Overview:
ANAB is a company operating in the Health Technology sector, specifically in the Biotechnology industry. The company has a market capitalization of $640,461,789. In this report, we will conduct a detailed analysis of ANAB's financial health, earnings and revenue growth, profitability, operating margin, ...
Technical Analysis of ANAB 2024-05-03
Overview:
In analyzing the technical indicators for ANAB over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and make informed predictions reg...
Recent News & Updates
- 2024-05-02 10:01
- 2024-05-01 22:01
- 2024-05-01 04:51
- 2024-04-30 16:51
- 2024-04-24 09:00
Actym Therapeutics Appoints Thomas Smart as CEO(PR Newswire)
- 2024-04-23 21:00
Actym Therapeutics Appoints Thomas Smart as CEO(Prnewswire)
- 2024-04-15 14:19
BTIG Research Predicts Over 118% Rally for These 3 Stocks(InvestorPlace)
- 2024-04-12 19:00
- 2024-04-09 14:40
- 2024-04-09 02:40
- 2024-03-18 06:32
- 2024-03-14 12:00
- 2024-03-14 09:55
- 2024-03-14 09:40
- 2024-03-14 00:00
- 2024-03-13 21:55
- 2024-03-11 17:30
- 2024-03-11 16:15
- 2024-03-11 05:30
- 2024-03-11 04:15
- 2024-02-29 10:00
- 2024-02-29 09:15
- 2024-02-28 20:15
- 2024-02-28 10:00
- 2024-02-27 21:00
- 2024-02-22 04:00
13 Best Short Squeeze Stocks To Buy Now(Insider Monkey)
- 2024-02-19 05:54
- 2024-02-18 16:54
- 2024-02-12 02:29
- 2024-01-31 09:15
Page 1 of 5
previousnext